Effectiveness of this strategy was demonstrated against pancreatic cancer using a PSCA-specific CAR engineered with an inverted IL-4/IL-7 chimeric cytokine receptor (4/7-ICR) (56), which contains an IL-4 extracellular domain fused to an activating IL-7 intracellular domain. Here, IL7 is linked to familial pancreatic carcinoma.